Natixis Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Natixis Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.21M	Buy	127,666 +57,965	+83%	+$794K	﹤0.01%	1192
2026 Q1	$866K	Buy	+69,701	New	+$936K	﹤0.01%	1402
2019 Q2	–	Sell	-17,474	Closed	-$248K	–	1060
2019 Q1	$248K	Buy	+17,474	New	+$231K	﹤0.01%	1039
2018 Q4	–	Sell	-22,022	Closed	-$489K	–	1079
2018 Q3	$489K	Buy	22,022 +1,094	+5%	+$23K	﹤0.01%	1037
2018 Q2	$343K	Buy	+20,928	New	+$367K	﹤0.01%	1053

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Natixis Advisors's AMRX Position: Q2 2026 in Review

Natixis Advisors increased its Amneal Pharmaceuticals (AMRX) stake by 83% in Q2 2026, buying an estimated $794K and bringing the position to 127,666 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

Natixis Advisors first reported a position in AMRX in Q2 2018 and has held it in 5 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Natixis Advisors held 127,666 shares of Amneal Pharmaceuticals worth $2.21M as of Q2 2026.
Natixis Advisors bought 57,965 Amneal Pharmaceuticals shares in Q2 2026, an estimated $794K.
Amneal Pharmaceuticals made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1192 holding.
Natixis Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 5 quarters since.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.